The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Netherlands

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Phase 2 · randomised · 353 people · 6 sites in Netherlands · Recruiting now

August 7, 2026
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

Phase 3 · randomised · 103 people · 25 sites in Netherlands · Recruiting now

August 7, 2026
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Phase 2 · randomised · 108 people · 59 sites in 15 countries · Running, not taking new patients

August 7, 2026
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Phase 2 · 560 people · 54 sites in 7 countries · Recruiting now

August 7, 2026
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Phase 2 · randomised · 80 people · 76 sites in 12 countries · Recruiting now

August 7, 2026
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

Phase 2 · randomised · 302 people · 109 sites in 22 countries · Running, not taking new patients

August 7, 2026
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Phase 3 · randomised · 461 people · 419 sites in 32 countries · Running, not taking new patients

August 7, 2026
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now

August 7, 2026
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Phase 3 · randomised · 400 people · 366 sites in 25 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now

August 7, 2026